Annovis Bio Inc. (NYSE: ANVS) to Present Recent Ac
Post# of 124
(Total Views: 85)
Posted On: 12/03/2024 3:13:25 PM
Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast
- The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST.
- Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session.
- The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to provide key operational highlights and year-end clinical updates (https://nnw.fm/3eqFH ).
The investor webcast will be led by Annovis’ CEO, Maria Maccecchini, Ph.D., who will share a comprehensive update on the company’s recent achievements, ongoing clinical programs and strategic initiatives for 2025.
Key topics addressed during the webcast will include:
Clinical Progress: Updates on Phase 3 studies for AD and PD.
Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (“FDA”) and upcoming submissions.
Financial Overview: Summary of the company’s financial health and funding strategies.
Strategic Outlook: Plans for advancing neurodegenerative disease therapies in the coming year.
The company recently received FDA clearance to proceed with a pivotal Phase 3 study for buntanetap in early AD, set to begin in Q1 2025. The FDA clearance came after the company presented encouraging results of a recently completed Phase 2/3 AD study which showed that buntanetap significantly improved cognition in patients with early AD by 3.3 points on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group.
Buntanetap is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.
A separate Phase 3 PD clinical trial indicated that buntanetap led to significant improvements in motor skills, daily functions and cognition in the per protocol PD population. The drug also halted cognitive decline in the intent-to-treat population. The company is now preparing for a meeting with the FDA to align on the next steps for its PD program, to be held in Q1 2025.
“Our priority is to bring a safe and effective treatment to patients, and we are committed to ensuring the next clinical trials are executed at the highest standards to attain an expedited NDA submission,” Dr. Maccecchini said in a recent episode of IBNs’ The BioMedWire Podcast (https://nnw.fm/zHWRg ).
Investors and parties interested in attending the webcast on Dec. 11 can register in advance (https://nnw.fm/EijEH ). During the event’s Q&A session, the Annovis CEO will also answer as many questions as possible, and participants are encouraged to submit their inquiries in advance via email at ir@annovisbio.com.
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X, and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST.
- Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session.
- The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to provide key operational highlights and year-end clinical updates (https://nnw.fm/3eqFH ).
The investor webcast will be led by Annovis’ CEO, Maria Maccecchini, Ph.D., who will share a comprehensive update on the company’s recent achievements, ongoing clinical programs and strategic initiatives for 2025.
Key topics addressed during the webcast will include:
Clinical Progress: Updates on Phase 3 studies for AD and PD.
Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (“FDA”) and upcoming submissions.
Financial Overview: Summary of the company’s financial health and funding strategies.
Strategic Outlook: Plans for advancing neurodegenerative disease therapies in the coming year.
The company recently received FDA clearance to proceed with a pivotal Phase 3 study for buntanetap in early AD, set to begin in Q1 2025. The FDA clearance came after the company presented encouraging results of a recently completed Phase 2/3 AD study which showed that buntanetap significantly improved cognition in patients with early AD by 3.3 points on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group.
Buntanetap is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.
A separate Phase 3 PD clinical trial indicated that buntanetap led to significant improvements in motor skills, daily functions and cognition in the per protocol PD population. The drug also halted cognitive decline in the intent-to-treat population. The company is now preparing for a meeting with the FDA to align on the next steps for its PD program, to be held in Q1 2025.
“Our priority is to bring a safe and effective treatment to patients, and we are committed to ensuring the next clinical trials are executed at the highest standards to attain an expedited NDA submission,” Dr. Maccecchini said in a recent episode of IBNs’ The BioMedWire Podcast (https://nnw.fm/zHWRg ).
Investors and parties interested in attending the webcast on Dec. 11 can register in advance (https://nnw.fm/EijEH ). During the event’s Q&A session, the Annovis CEO will also answer as many questions as possible, and participants are encouraged to submit their inquiries in advance via email at ir@annovisbio.com.
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X, and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)